Quantcast
Last updated on April 24, 2014 at 5:50 EDT

Latest Fentanyl Stories

Heroin Mixed With Fentanyl Causes Concerns In Pennsylvania
2014-01-29 04:58:36

redOrbit Staff & Wire Reports - Your Universe Online Fentanyl, a powerful narcotic used by cancer patients as a pain reliever, is being blamed for nearly two-dozen heroin-related deaths in Pennsylvania in recent days, state officials told various media outlets on Tuesday. According to Lorenzo Ferrigno and Kevin Conlon of CNN, Allegheny County chief medical examiner Dr. Karl Williams confirmed that 15 of the deaths occurred in the past week, involving both men and women between the...

2014-01-10 08:23:03

BEMA Buprenorphine Phase 3 opioid naive study database lock imminent; triggers $10M milestone payment from Endo Pharmaceuticals RALEIGH, N.C., Jan. 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced updates to the company's anticipated 2014 milestones for its product portfolio, including the imminent database lock for the Phase 3 clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic pain in opioid naive subjects, with...

2013-12-16 08:25:46

- FDA establishes the PDUFA action date of July 27, 2014 for Zalviso - REDWOOD CITY, Calif. and AACHEN, Germany, Dec. 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal GmbH announced today that they have entered into a commercial collaboration, covering the territory of the European Union, certain other European countries and Australia for ZALVISO(TM) (previously known as ARX-01) for potential use in pain treatment within or dispensed by a hospital,...

2013-12-13 08:24:43

- 30 mcg sufentanil NanoTab treatment group experienced rapid onset of action with statistically significant pain relief and reduced pain intensity at 30 minutes - REDWOOD CITY, Calif., Dec. 13, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today presented additional detail from the Phase 2 dose-finding study...

2013-12-03 08:33:07

STAMFORD, Conn., Dec. 3, 2013 /PRNewswire/ -- Purdue Pharma L.P. and Impax Laboratories, Inc. announced today that the companies have agreed to resolve the patent infringement lawsuits between them now pending in the United States District Court for the Southern District of New York concerning certain Purdue patents, including patents for abuse-deterrent technology, protecting OxyContin® (oxycodone HCl controlled-release) Tablets CII ("OxyContin"). According to the agreement, Purdue and...

2013-12-02 08:31:05

NEWARK, Calif., Dec. 2, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Piper Jaffray 25(th) Annual Healthcare Conference at The New York Palace Hotel in New York City. The presentation at the Piper conference is scheduled for 12:10 pm EST (9:10 am PST) on Tuesday, December 3, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A...

2013-12-02 08:30:47

REDWOOD CITY, Calif., Dec. 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the Zalviso(TM) New Drug Application (NDA) was accepted for filing by the FDA on November 26, 2013. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to...

2013-11-25 08:26:28

RALEIGH, N.C., Nov. 25, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 25(th) Annual Piper Jaffray Healthcare Conference. The presentation is scheduled for Wednesday, December 4, 2013 at 1:00 p.m. Eastern Time at The New York Palace. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) BDSI submitted a New Drug Application (NDA) for BUNAVAIL...

2013-11-12 16:26:57

BUNAVAIL NDA Filed; PDUFA date June 7, 2014 RALEIGH, N.C., Nov. 12, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming milestones for 2013 and 2014. (Logo:...